These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 15682332

  • 1. Early-stage [123I]beta-CIT SPECT and long-term clinical follow-up in patients with an initial diagnosis of Parkinson's disease.
    Stoffers D, Booij J, Bosscher L, Winogrodzka A, Wolters EC, Berendse HW.
    Eur J Nucl Med Mol Imaging; 2005 Jun; 32(6):689-95. PubMed ID: 15682332
    [Abstract] [Full Text] [Related]

  • 2. Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease.
    Scherfler C, Seppi K, Donnemiller E, Goebel G, Brenneis C, Virgolini I, Wenning GK, Poewe W.
    Brain; 2005 Jul; 128(Pt 7):1605-12. PubMed ID: 15817519
    [Abstract] [Full Text] [Related]

  • 3. Imaging of dopamine transporters and D2 receptors in patients with Parkinson's disease and multiple system atrophy.
    Knudsen GM, Karlsborg M, Thomsen G, Krabbe K, Regeur L, Nygaard T, Videbaek C, Werdelin L.
    Eur J Nucl Med Mol Imaging; 2004 Dec; 31(12):1631-8. PubMed ID: 15583914
    [Abstract] [Full Text] [Related]

  • 4. Functional morphometry of the striatum in Parkinson's disease on three-dimensional surface display of 123I-beta-CIT SPECT data.
    Ichise M, Kim YJ, Erami SS, Ballinger JR, Vines D, Tanaka F, Lang AE.
    J Nucl Med; 1999 Apr; 40(4):530-8. PubMed ID: 10210210
    [Abstract] [Full Text] [Related]

  • 5. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients.
    Seibyl JP, Marek K, Sheff K, Zoghbi S, Baldwin RM, Charney DS, van Dyck CH, Innis RB.
    J Nucl Med; 1998 Sep; 39(9):1500-8. PubMed ID: 9744331
    [Abstract] [Full Text] [Related]

  • 6. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.
    Tissingh G, Booij J, Bergmans P, Winogrodzka A, Janssen AG, van Royen EA, Stoof JC, Wolters EC.
    J Nucl Med; 1998 Jul; 39(7):1143-8. PubMed ID: 9669384
    [Abstract] [Full Text] [Related]

  • 7. Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study.
    Pirker W, Djamshidian S, Asenbaum S, Gerschlager W, Tribl G, Hoffmann M, Brücke T.
    Mov Disord; 2002 Jan; 17(1):45-53. PubMed ID: 11835438
    [Abstract] [Full Text] [Related]

  • 8. Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients.
    Seibyl JP, Marek K, Sheff K, Baldwin RM, Zoghbi S, Zea-Ponce Y, Charney DS, van Dyck CH, Hoffer PB, Innis RB.
    J Nucl Med; 1997 Sep; 38(9):1453-9. PubMed ID: 9293807
    [Abstract] [Full Text] [Related]

  • 9. 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism.
    Lorberboym M, Djaldetti R, Melamed E, Sadeh M, Lampl Y.
    J Nucl Med; 2004 Oct; 45(10):1688-93. PubMed ID: 15471834
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Measuring the rate of progression of Parkinson's disease over a 5-year period with beta-CIT SPECT.
    Pirker W, Holler I, Gerschlager W, Asenbaum S, Zettinig G, Brücke T.
    Mov Disord; 2003 Nov; 18(11):1266-72. PubMed ID: 14639666
    [Abstract] [Full Text] [Related]

  • 20. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy.
    Brücke T, Asenbaum S, Pirker W, Djamshidian S, Wenger S, Wöber C, Müller C, Podreka I.
    J Neural Transm Suppl; 1997 Nov; 50():9-24. PubMed ID: 9120429
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.